Morning Money: How did Sareum Holdings perform in its final results? CEO Dr Tim Mitchell discussed

  • Home
  • /
  • Podcasts
  • /
  • Morning Money: How did Sareum Holdings perform in its final results? CEO Dr Tim Mitchell discussed - 02 Nov 16
Sarah Lowther

Morning Money: How did Sareum Holdings perform in its final results? CEO Dr Tim Mitchell discussed

Sarah Lowther
Original Broadcast:

Morning Money at 6:00

Morning Money: How did Sareum Holdings perform in its final results? CEO Dr Tim Mitchell discussed
Just five weeks ago, shares in Sareum Holdings rocketed over 150% after it announced its cancer drug candidate had been licensed to Nasdaq listed ProNAi Therapeutics. The company discovers and develops innovative drug candidates aimed at cancers and autoimmune diseases and its results are out. Dr Tim Mitchell is the CEO and he joined Share Radio to discuss the numbers.
Guests:

Chris Bailey,Dr Tim Mitchell


Published:

Topics: UK (in Economics); Profiles (in Work)

Strand: Morning Money


View all podcasts